This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

About CRESEMBA®About CRESEMBA®Meet CRESEMBA®CRESEMBA® in the ICUCRESEMBA® in ActionEfficacy EfficacyInvasive AspergillosisEfficacyGuidelines MucormycosisEfficacyGuidelinesSafetySafetyTolerabilityInvasive AspergillosisMucormycosis Safety ProfileSafety ProfileDosingDosingSimple DosingLinear PKs, Low Variability and TDMPractical ConsiderationsReal-world DataReal-world DataReal-world EffectivenessReal-world SafetyResourcesResourcesSummary of Prescribing InformationEventsMaterialsVideos

Antimould efficacy proven in the real world1–4

The efficacy of CRESEMBA® has been proven in clinical practice1–4

  

CRESEMBA® has been used in over 91,000 people5 and has proven effective against invasive aspergillosis and mucormycosis in clinical practice.1–4 

  

In a real-world retrospective study in invasive aspergillosis, CRESEMBA® was associated with higher survival rates than other antifungals.6

  

CRESEMBA® has proven effective in different patient populations and infection sites in clinical practice.3

  

In a retrospective US cohort study, CRESEMBA® achieved good treatment responses in varied patient groups, including those receiving prior azole prophylaxis.3

  

Response rates at Day 42 in patients who received ≥3 CRESEMBA® doses at a large US centre (2015–2017, n=91)3,a

Adapted from reference 3.

a. The fungal pathogen was identified in 38 patients, Aspergillus (n=17) and Mucorales (n=10) being the most common. Partial and complete response were defined in accordance with the MSG/EORTC consensus criteria.

 Response rates at Day 42 in patients who received ≥3 CRESEMBA® doses at a large US centre (2015–2017, n=91)3,a

Adapted from reference 3.

a. The fungal pathogen was identified in 38 patients, Aspergillus (n=17) and Mucorales (n=10) being the most common. Partial and complete response were defined in accordance with the MSG/EORTC consensus criteria.

AmB, amphotericin B; EORTC, European Organization for Research and Treatment of Cancer; IA, invasive aspergillosis; MSG, Mycoses Study Group.​​​​​​

  

Prescribing Information:

CRESEMBA® (isavuconazole)

References:

Monforte A et al. ECCMID 2020. Abstract 8095.Cattaneo C et al. Hemasphere 2019;3(6):e320.Hassouna H et al. Mycoses 2019;62(6):534–541.DiPippo AJ and Kontoyiannis DP. Clin Infect Dis 2019;69(9):1624–1627.Basilea. CRESEMBA® Periodic Safety Update Report 9. September 2020. DOF.Duval C et al. EHA 2018. Abstract PF455.Adapted from Local Product Document of CRESEMBA® (Isavuconazole) version LPDCRE052021.

   

PP-CRB-IND-0472 July 2022

   

Real-world Data Simplicity and flexibility7 for the challenges of daily practice Explore Dosing Loading Simplicity and flexibility7 for the challenges of daily practice Explore Dosing Loading Explore CRESEMBA® efficacy in invasive aspergillosis (IA) and mucormycosis, and learn about the pivotal clinical trials IA Efficacy Loading Mucormycosis Efficacy Loading

Example

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-CRB-IND-0472

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023